Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RPTX |
---|---|---|
09:32 ET | 796 | 3.57 |
09:34 ET | 300 | 3.6066 |
09:36 ET | 1020 | 3.56 |
09:38 ET | 323 | 3.5513 |
09:39 ET | 1800 | 3.5299 |
09:41 ET | 2298 | 3.51 |
09:52 ET | 1100 | 3.53 |
09:56 ET | 206 | 3.5113 |
09:59 ET | 209 | 3.5112 |
10:01 ET | 534 | 3.53 |
10:10 ET | 100 | 3.52 |
10:14 ET | 150 | 3.51 |
10:21 ET | 100 | 3.5224 |
10:37 ET | 1000 | 3.52 |
10:39 ET | 6496 | 3.51 |
10:42 ET | 1400 | 3.51 |
10:44 ET | 100 | 3.51 |
10:48 ET | 1600 | 3.49 |
10:50 ET | 300 | 3.5086 |
10:51 ET | 522 | 3.4931 |
10:53 ET | 100 | 3.5102 |
10:57 ET | 2936 | 3.49 |
11:00 ET | 800 | 3.51 |
11:02 ET | 100 | 3.52 |
11:04 ET | 6389 | 3.505 |
11:11 ET | 100 | 3.49 |
11:18 ET | 500 | 3.49 |
11:22 ET | 2573 | 3.48 |
11:24 ET | 4532 | 3.485 |
11:26 ET | 500 | 3.485 |
11:27 ET | 100 | 3.4805 |
11:31 ET | 100 | 3.48 |
11:33 ET | 691 | 3.48 |
11:36 ET | 200 | 3.47 |
11:49 ET | 200 | 3.475 |
11:51 ET | 2313 | 3.48 |
11:54 ET | 834 | 3.5 |
11:56 ET | 2100 | 3.5 |
12:00 ET | 300 | 3.51 |
12:02 ET | 300 | 3.52 |
12:07 ET | 500 | 3.53 |
12:09 ET | 2000 | 3.52 |
12:18 ET | 1533 | 3.5634 |
12:20 ET | 200 | 3.53 |
12:23 ET | 995 | 3.57 |
12:30 ET | 200 | 3.56 |
12:32 ET | 875 | 3.55 |
12:56 ET | 200 | 3.56 |
12:57 ET | 400 | 3.56 |
12:59 ET | 300 | 3.59 |
01:17 ET | 300 | 3.6 |
01:19 ET | 100 | 3.58 |
01:21 ET | 977 | 3.6187 |
01:24 ET | 200 | 3.6 |
01:28 ET | 100 | 3.6 |
01:30 ET | 10500 | 3.51 |
01:32 ET | 300 | 3.53 |
01:35 ET | 100 | 3.52 |
01:39 ET | 444 | 3.52 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Repare Therapeutics Inc | 151.5M | -3.2x | --- |
AVITA Medical Inc | 211.6M | -4.5x | --- |
Precision BioSciences Inc | 83.7M | -2.2x | --- |
Genfit SA | 186.8M | -6.0x | --- |
Champions Oncology Inc | 65.4M | -6.5x | --- |
Innate Pharma SA | 205.6M | -25.2x | --- |
Repare Therapeutics Inc. is a clinical-stage precision oncology company focused on the development of synthetic lethality (SL)-based therapies for patients with cancer. The Company is engaged in the proprietary SL approach to the discovery and development of novel therapeutics. It uses its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The Company’s initial product candidate, camonsertib (RP-3500 or RG6526), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated kinase (ATM) gene as part of a network of 16 STEP2-identified genomic alterations. Its other pipeline includes Lunresertib PKMYT1 Inhibitor and RP-3467 polymerase theta (Pol0) Inhibitor.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $151.5M |
---|---|
Revenue (TTM) | $97.9M |
Shares Outstanding | 42.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.75 |
EPS | $-1.10 |
Book Value | $5.03 |
P/E Ratio | -3.2x |
Price/Sales (TTM) | 1.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -72.27% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.